Skip to main content
ALGORAE PHARMACEUTICALS LIMITED logo

ALGORAE PHARMACEUTICALS LIMITED — Investor Relations & Filings

Ticker · 1AI ISIN · AU0000296022 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,159 across all filing types
Latest filing 2018-11-06 Director's Dealing
Country AU Australia
Listing ASX 1AI

About ALGORAE PHARMACEUTICALS LIMITED

https://algoraepharma.com/

Algorae Pharmaceuticals Limited is a biopharmaceutical company focused on the discovery and development of novel therapeutic solutions for complex medical conditions. The company leverages its proprietary artificial intelligence platform, AlgoraeOS, to streamline the drug discovery process and identify synergistic drug combinations. Its research pipeline primarily targets neurodegenerative diseases and other areas of high unmet clinical need. Key development programs include AI-116, a combination therapy aimed at treating dementia and Alzheimer's disease. By integrating advanced computational modeling with traditional pharmacological research, the company seeks to accelerate the transition of candidates from preclinical stages to clinical trials, optimizing therapeutic efficacy and safety profiles.

Recent filings

Filing Released Lang Actions
Change of Director's Interest Notice - R Elliott 2 pages 242.9KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details a director's change in shareholding, including the number of shares held before and after the transaction, the date of change, and the nature of the transaction (on-market trade). This is a report of personal share transactions by a company director, which matches the definition of 'Director's Dealing' filings. The document length is 3372 characters, which is consistent with a detailed notice of director's share transactions rather than a full financial report or announcement. Therefore, the correct classification is DIRS (Director's Dealing).
2018-11-06 English
NTCELL Parkinsons trial patient data at 18 months 3 pages 516.9KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement from Living Cell Technologies Limited dated 02 November 2018. It reports on patient data 18 months after implantation in a Phase IIb clinical trial for NTCELL treatment for Parkinson's disease. The content focuses on clinical trial results, efficacy data, and future strategy discussions. There are no financial statements, regulatory certifications, or detailed financial performance data. The document is a company announcement about clinical trial progress and patient data, not a financial report or regulatory filing. It is not a report publication announcement since it contains substantive data and analysis rather than just a notice of report availability. The document fits best as a Regulatory Filings (RNS) category, which covers general regulatory announcements and miscellaneous filings that do not fit other categories.
2018-11-01 English
Appendix 4C - quarterly 7 pages 321.8KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Appendix 4C Quarterly Cash Flow Report 30 September 2018' and is an ASX announcement. It contains detailed quarterly cash flow statements, including operating, investing, and financing activities, as well as cash balances and estimated cash outflows for the next quarter. The document references compliance with Listing Rule 4.7B, which pertains to quarterly reports for entities listed on the ASX. The content is a comprehensive quarterly financial report with actual financial data and analysis for a period shorter than a full fiscal year. It is not merely an announcement of a report or a certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q1 2019
2018-10-25 English
Response to ASX Price Query 3 pages 436.7KB
Regulatory Filings Classification · 95% confidence The document is a letter from the Australian Securities Exchange (ASX) to Living Cell Technologies Limited regarding a price query about recent trading activity in the company's securities. The letter requests the company to respond to specific questions about any undisclosed information that might explain the trading, compliance with listing rules, and disclosure policies. The company's response confirms no undisclosed information exists and compliance with listing rules. This document is a regulatory communication related to market disclosure and compliance, not a financial report, earnings release, or other specific report type. It is a regulatory filing that addresses compliance with continuous disclosure obligations under ASX Listing Rules. The document length is 7091 characters, which is relatively short and focused on regulatory compliance rather than financial data or report publication. Therefore, the appropriate classification is Regulatory Filings (RNS).
2018-10-18 English
Notice of Annual General Meeting/Proxy Form 12 pages 467.6KB
AGM Information Classification · 100% confidence The document is titled 'NOTICE OF ANNUAL GENERAL MEETING' and details the date, time, and place of the meeting. It includes the agenda items such as consideration of the Financial Report, adoption of the Remuneration Report, re-election and election of directors, and approval of share options. It also contains explanatory notes and voting exclusions related to the AGM. The document is a notice to shareholders about the upcoming Annual General Meeting and the resolutions to be considered, rather than the actual Annual Report or financial statements. The length of the document (15,000 characters) is consistent with a detailed AGM notice. Therefore, this document fits the category of AGM Information (AGM-R).
2018-10-14 English
Annual Report to shareholders 44 pages 1.3MB
Annual Report Classification · 100% confidence The document is titled '2017 - 2018 ANNUAL REPORT' and contains detailed sections typical of an annual report, including Chairman's and CEO's messages, significant events, directors' report, auditor's independence declaration, consolidated financial statements, notes to financial statements, directors' declaration, and independent auditor's report. The length is substantial (15,000 characters), indicating a full report rather than a brief announcement. The content covers comprehensive financial performance, corporate governance, strategy, and operational updates for the fiscal year 2017-2018. These characteristics align with the definition of an Annual Report (10-K). FY 2018
2018-10-14 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.